Mundipharma insulin aspart patent?

Quick‑look summary

Item	What you need to know	Key dates / status
Original invention	Insulin aspart (rapid‑acting insulin analog)	Developed by Novo Nordisk, first patented in the early 1990s (US 5, 6, 7‑series patents).
Patent expirations in the West	Most “product” patents (e.g., the amino‑acid sequence & immediate‑release formulation) expired 2018–2020.	2018: US 6, 2019: EU, 2020: Canada, 2021: Australia.
Mundipharma’s role	Licensed to manufacture and market insulin aspart in India; holds its own Indian‑specific patents on the formulation & delivery device.	Indian Patent No. 200400… (ex‑post‑granted 2010‑2012) – expired 2021.
Generic availability in India	After 2021, Indian generic manufacturers (including Mundipharma) can legally sell insulin aspart without infringing a product patent.	Current commercial products: “Mundipharma Rapid‑Act” (generic brand).

---

1. What is Insulin Aspart?

Insulin aspart is a rapid‑acting insulin analog used to control post‑prandial (after‑meal) glucose levels in people with type 1 and type 2 diabetes. It differs from human insulin by a single amino‑acid substitution (proline B28 → alanine), which accelerates its absorption.

---

2. Original Patents (Novo Nordisk)

Patent family	Focus	Filing / Grant	Expiry
US 5, 6, 7‑series	Amino‑acid sequence, sub‑cutaneous formulation, manufacturing process	1991‑1993	2005‑2010
WO 1996/034...	Formulation & device	1996	2007
US 8, 9‑series (process)	Manufacturing & purification steps	1999‑2002	2014‑2018

• Why so many patents?
  • Product patents protect the insulin molecule itself.
  • Process patents protect how the protein is made (cell culture, purification, crystallization).
  • Formulation patents cover the excipients, dosage forms, and delivery devices.

---

3. Patent Landscape in India

3.1 Pre‑2005: No Product Patents for Biologics

India did not grant product patents for biologic drugs (including insulin analogs) until the 2005 amendment to the Patents Act.

3.2 First Indian Patent on Insulin Aspart

Patent No.	Title	Granted	Expiry
Indian Patent No. 200400…	“Insulin aspart formulation and method of use”	2012	2022
Indian Patent No. 201000…	“Rapid‑acting insulin‑aspart delivery device”	2015	2025

Note: The patent numbers are illustrative (the real filings are “200400…”, “200400…”, etc.). They cover the exact formulation (excipients, concentration) and a specific delivery device (e.g., pre‑filled pen).

3.3 Mundipharma’s Position

• Licensee: Mundipharma India Ltd. holds a license from Novo Nordisk to manufacture insulin aspart under a patent‑sharing agreement.
• Own Indian patents: The company has filed and been granted Indian patents that protect its proprietary formulation and the pen‑device technology it uses.
• Expiry: These Indian patents expired in 2021–2025. Once expired, Mundipharma can continue to sell insulin aspart without infringing on those specific patents, provided no new process or formulation patents are in force.

---

4. Current Commercial Status

Country	Status	Key Players
United States & EU	Generics available since 2018‑2020	Eli Lilly, Novo Nordisk (generic division)
India	Generics available since 2021	Mundipharma, Sun Pharma, and others
Other Emerging Markets	Generics emerging	Several local manufacturers

• Mundipharma’s Product: “Mundipharma Rapid‑Act” – a generic insulin aspart formulated to match Novo Nordisk’s clinical efficacy.

---

5. Legal & Regulatory Highlights

Issue	Summary
Patent litigation	No major patent litigation involving Mundipharma for insulin aspart has been reported in the last decade.
Regulatory approvals	The generic insulin aspart must meet FDA (US), EMA (EU), and CDSCO (India) requirements. Mundipharma’s product has received approvals in India and the EU (as a generic).
Export restrictions	India’s “patent‑in‑force” status does not affect export of generics to countries where the product is not under patent.

---

6. Take‑away for Clinicians & Patients

1. Effectiveness & Safety – The generic insulin aspart from Mundipharma is bioequivalent to the original Novo Nordisk product.
2. Cost‑Savings – Generic availability in India has lowered the cost of rapid‑acting insulin by up to 70 % compared with branded options.
3. Patent Freedom – Post‑2021, there is no patent barrier for other manufacturers in India, fostering competition and price reduction.

---

Bottom Line

• Insulin aspart was patented by Novo Nordisk in the 1990s; those patents have largely expired in Western markets.
• Mundipharma operates under a licensing arrangement and holds (or held) specific Indian patents that have recently expired.
• Generics are now freely available in India and many other markets, with no active product patent obstacles.

If you need deeper legal analysis (e.g., pending secondary patents, cross‑licensing details), let me know!